PPT-Atlantic Cardiovascular Patient Outcomes Research Team

CPORT E Trial Randomized trial comparing medical economic and quality of life outcomes of nonprimary PCI at hospitals with and without onsite cardiac surgery Motivation for Trial Sustain primary PCI program at noSOS hospitals. What is PCORI?. PROSPER is funded by PCORI . PCORI . =Patient Centered Outcomes . . Research Institute. Nonprofit organization established . . by the Affordable Care Act in 2010. PCORI’s Mission. . Support for Researchers Working with Public & Patient Groups. Susan Hrisos, Senior Research Associate. & Dave Green, PPI representative . May 2014. Format of session. Introduction to Patient & Public Involvement in Research. Study Procedures and Data Elements, Sources, Uses, and Issues . Thomas Delate, PhD, MS. Clinical Pharmacy Research Scientist. Learning Objectives. Class 3: Study Procedures and Data Elements, Sources, Uses, and Issues . CAPriCORN. ). 1. Creating Authentic Community-Academic Partnerships in Clinical Research: . C. hicago . A. rea . P. atient . C. entered . O. utcomes . R. esearch . N. etwork’s. Patient and Clinician Advisory Committee (PCAC) . FDA-Mandated CV Safety Trials. 1. TECOS. (Trial Evaluating Cardiovascular Outcomes with Sitagliptin). Clinical Outcomes with Antihyperglycemic Agents. 2. Clinical Outcomes with Sitagliptin. Study Design. . Joe Selby, MD MPH. Executive Director, PCORI. Florida State University System. 4. th. Annual Federal R&D . Agency Workshop. September 30, 2016. FOR TODAY. “. The . purpose of the Institute is to . National Library of Medicine. Webinar Part II. HTA-CER-PM-PCOR: Converging on What Works for Patients. September 7, 2011. Clifford Goodman, PhD. The Lewin Group. Falls Church, Virginia USA. clifford.goodman@lewin.com. CAPriCORN. ). 1. Creating Authentic Community-Academic Partnerships in Clinical Research: . C. hicago . A. rea . P. atient . C. entered . O. utcomes . R. esearch . N. etwork’s. Patient and Clinician Advisory Committee (PCAC) . CVOTs. 1. FDA CVOT Guidance—2008. Timeline of Major Diabetes. Outcomes Trials. 2. Blue. = Intensive vs standard control using same set of glucose-lowering agent(s). Purple. = Intensive control with a specific agent vs standard care. David J Albrecht D.O.. Heart & Vascular 2018 Winter Conference. Cardiovascular risk . m. odification in relation to current diabetes management . therapies. Case study highlighting the therapeutic decisions . 12:41 Remote Monitoring Devices �� &#x/MCI; 20;&#x 000;&#x/MCI; 20;&#x 000; &#x/BBo;&#xx [1; .1;ő ;Đ.;遷&#x 578;&#x.136; 76;.32; ];&#x/Typ; /L; you;&#x Second Annual Retreat. December 11. th. , 2017 . Nadia . Giannetti. . MD. Chief. , Division of Cardiology . MUHC. Ariane Marelli . MD, . MPH. Director of Cardiovascular Research . MUHC. Background. In spring 2017, a grid developed to categorize tertiary and quaternary clinical activities across the McGill RUIS. Management and Outcomes of Congenital Anomalies in Low-, Middle- and High-Income Countries: . A Multi-centre, International, Prospective Cohort Study. Congenital Anomalies Globally. GBD Study 2015. 2015:. Workshop. 1. Workshop Goals. Participants will increase their medical, scientific, and advocacy skills so they can improve the design, implementation, and dissemination of celiac disease research.. 2.